Genome Company receives FDA IND clearance for GEN-001, its f...
SEOUL, South Korea, April 20, 2020/PRNewswire-AsiaNet/-- - Asia's first company to sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug - Enables to initiate Phase 1/1b clinical trial on combinational therapy of Merck KGaA, Darmstadt, Germany/Pfizer's ...
Authors: LATEST ASIANET NEWS RELEASES